Drug Trial Radar · NCT07350577
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 17, 2025
Primary completion
Apr 6, 2026
Study completion Apr 6, 2026
Sponsor
- Lead sponsor
- AltruBio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.
Conditions
- Ulcerative Colitis (UC)
Interventions
ALTB-268Biological
monoclonal antibody
PlaceboOther
Saline solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - Adverse EventsTime frame: Through study completion, up to day 71 of the study
- To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - Infusion Site AssessmentsTime frame: Through study completion, up to day 71 of the study
- To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - C-SSRSTime frame: Through study completion, up to day 71 of the study
- To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - PHQ-8Time frame: Through study completion, up to day 71 of the study
- To evaluate the safety and tolerability of ALTB-268 following intravenous (IV) infusion in healthy participants - Clinical Laboratory TestTime frame: Through study completion, up to day 71 of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health Clinical Research Services, LLC
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.